Association between COMT genotype and development of breast cancer according to menopausal status
| Genotype . | Case n (%) . | Control n (%) . | ORa (95% CI) . |
|---|---|---|---|
| All | |||
| HH | 115 (23.9) | 100 (20.8) | 1.0 |
| HL | 238 (49.5) | 237 (49.4) | 0.84 (0.59–1.20) |
| LL | 128 (26.6) | 143 (29.8) | 0.75 (0.51–1.11) |
| HL or LL | 366 (76.1) | 380 (79.2) | 0.81 (0.58–1.13) |
| Premenopausal | |||
| HH | 44 (26.8) | 41 (20.3) | 1.0 |
| HL | 79 (48.2) | 112 (55.4) | 0.63 (0.37–1.09) |
| LL | 41 (25.0) | 49 (24.3) | 0.70 (0.37–1.31) |
| HL or LL | 120 (73.2) | 161 (79.7) | 0.65 (0.39–1.09) |
| Postmenopausal | |||
| HH | 71 (22.4) | 59 (21.2) | 1.0 |
| HL | 159 (50.2) | 125 (45.0) | 1.04 (0.65–1.68) |
| LL | 87 (27.4) | 94 (33.8) | 0.81 (0.48–1.35) |
| HL or LL | 246 (77.6) | 219 (78.8) | 0.94 (0.61–1.47) |
| Genotype . | Case n (%) . | Control n (%) . | ORa (95% CI) . |
|---|---|---|---|
| All | |||
| HH | 115 (23.9) | 100 (20.8) | 1.0 |
| HL | 238 (49.5) | 237 (49.4) | 0.84 (0.59–1.20) |
| LL | 128 (26.6) | 143 (29.8) | 0.75 (0.51–1.11) |
| HL or LL | 366 (76.1) | 380 (79.2) | 0.81 (0.58–1.13) |
| Premenopausal | |||
| HH | 44 (26.8) | 41 (20.3) | 1.0 |
| HL | 79 (48.2) | 112 (55.4) | 0.63 (0.37–1.09) |
| LL | 41 (25.0) | 49 (24.3) | 0.70 (0.37–1.31) |
| HL or LL | 120 (73.2) | 161 (79.7) | 0.65 (0.39–1.09) |
| Postmenopausal | |||
| HH | 71 (22.4) | 59 (21.2) | 1.0 |
| HL | 159 (50.2) | 125 (45.0) | 1.04 (0.65–1.68) |
| LL | 87 (27.4) | 94 (33.8) | 0.81 (0.48–1.35) |
| HL or LL | 246 (77.6) | 219 (78.8) | 0.94 (0.61–1.47) |
ORs and 95% CIs adjusted for age, age at menarche, age at first full-term pregnancy, number of full-term pregnancies, first-degree family history of breast cancer, history of benign breast disease, postmenopausal use of estrogen, and BMI.